date,title,source
Oct-17-18,"Report: Exploring Fundamental Drivers Behind CURO Group, BiondVax Pharmaceuticals, AMAG Pharmaceuticals, AcelRx Pharmaceuticals, Ballard Power, and Rhythm Pharmaceuticals  New Horizons, Emerging Trends, and Upcoming Developments",GlobeNewswire
Oct-22-18,BiondVax Receives 8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial,PR Newswire
Oct-24-18,"BiondVax's Universal Flu Vaccine Phase 3 Clinical Trial Completes First Season's Enrollment of 4,098 Participants",PR Newswire
Nov-13-18,BiondVax Announces Third Quarter 2018 Financial Results,PR Newswire
Nov-19-18,BiondVax Issues Clarification Regarding Third Quarter 2018 Financial Results,PR Newswire
Nov-20-18,BVXV: Enrollment of First Season Cohort Complete in Phase 3 Trial of Universal Influenza Vaccine,Zacks Small Cap Research
Nov-26-18,BiondVax CEO to Present at 'World Vaccine Congress 2018 San Diego' About BiondVax's Phase 3 Universal Flu Vaccine Candidate,PR Newswire
Nov-28-18,"Analysis: Positioning to Benefit within Real Goods Solar, Natural Resource Partners LP, Spark Therapeutics, Social Reality, Rapid7, and BiondVax Pharmaceuticals  Research Highlights Growth, Revenue, and Consolidated Results",GlobeNewswire
Mar-21-19,Last Participant out in USA Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate,PR Newswire
Mar-28-19,BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at IVW2019 Conference,PR Newswire
Apr-15-19,BiondVax Universal Flu Vaccine Patent Application Accepted in Australia,PR Newswire
Apr-17-19,BVXV: Update on Phase 3 Clinical Trial of Universal Influenza Vaccine,Zacks Small Cap Research
Apr-22-19,European Investment Bank (EIB) Extends Financing Agreement to 24 Million Total in Support of BiondVax's Universal Flu Vaccine Ongoing Pivotal Phase 3 Clinical Trial,PR Newswire
Apr-30-19,BiondVax Announces Fourth Quarter and Full Year 2018 Financial Results and Update,PR Newswire
May-13-19,BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at 18th MIXiii-BIOMED Conference,PR Newswire
May-30-19,BiondVax Announces First Quarter 2019 Financial Results,PR Newswire
